Follicular Lymphoma Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's, "Follicular Lymphoma Pipeline Insight, 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Follicular Lymphoma Treatment Drugs @ Follicular Lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Follicular Lymphoma Pipeline Report

* In August 2025, Celgene announced a study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
* In August 2025, Epizyme, Inc . conducted a study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed.
* In August 2025, Hoffmann-La Roche announced a study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.
* DelveInsight's Follicular Lymphoma Pipeline analysis depicts a robust space with 45+ Follicular Lymphoma companies working to develop 50+ pipeline treatment therapies.
* The leading Follicular Lymphoma Companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene and others.
* Promising Follicular Lymphoma Pipeline Therapies such as DRL_RI (Proposed rituximab biosimilar), MabThera Registered , Epcoritamab, Rituximab, Lenalidomide, and others.

Find out more about Follicular Lymphoma Therapeutics Assessment @ Follicular Lymphoma Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Follicular Lymphoma Emerging Drugs

* MIL62: MAB WORKS

MIL62 is a third-generation anti-CD20 antibody with a unique competitive position. MIL62 is the first domestically developed third-generation anti-CD20 antibody entering Phase III registration trial in China. MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab. Currently the drug is in Phase III stage of its development for the treatment of follicular lymphoma.

* AZD0486: AstraZeneca

AZD0486, also known as TNB-486, is an innovative bispecific antibody targeting CD19 and CD3, designed to enhance T-cell-mediated destruction of malignant B cells, particularly in patients with relapsed or refractory follicular lymphoma (FL). AZD0486 functions by engaging T-cells to attack B-cell malignancies, thereby circumventing some limitations associated with traditional therapies. Its design incorporates a low-affinity anti-CD3 moiety, which helps mitigate severe cytokine release syndrome (CRS), a common side effect of T-cell engagers. This unique feature allows for a more controlled immune response, potentially leading to better safety profiles. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Follicular Lymphoma.

* Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Abx) is a novel, potent, orally administered pan-histone deacetylase inhibitor (HDACi) developed by Xynomic Pharmaceuticals. It is designed to maintain effective anti-tumor concentrations through twice-daily (BID) dosing. Abexinostat targets multiple HDAC enzymes, which are involved in the deacetylation of histones, leading to chromatin remodeling and regulation of gene expression. By inhibiting HDACs, Abexinostat causes the accumulation of acetylated histones, promoting apoptosis, cell cycle arrest, and inhibition of angiogenesis in cancer cells. Additionally, Abexinostat acts as a Rad51 recombinase inhibitor, interfering with DNA repair mechanisms, which enhances its anti-cancer activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Follicular Lymphoma.

* ABBV-319: AbbVie

ABBV-319 is a CD19-targeting antibody-drug conjugate engineered to reduce glucocorticoid-associated toxicities while possessing 3 distinct mechanisms of action (MOA) to increase therapeutic efficacy: (1) antibody-mediated delivery of a glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced fragment crystallizable (Fc)-mediated effector function via afucosylation of the antibody backbone. Currently, the drug is in the Phase I stage of development to treat Follicular Lymphoma.

* NX-2127: Nurix Therapeutics, Inc.

NX-2127 is an oral small molecule degrader of BTK and cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos). Cereblon immunomodulatory drugs that induce degradation IKZF1 and IKZF3 such as lenalidomide and pomalidomide are FDA approved for a variety of hematologic malignancies including multiple myeloma, follicular lymphoma, and mantle cell lymphoma. We hypothesize that the combination of BTK degradation and cereblon immunomodulatory activity will have enhanced therapeutic benefit in patients suffering from a variety of B-cell malignancies. Initial clinical data support the activity of NX-2127 in patients whose tumors harbor either wild-type BTK or BTK with mutations conferring clinical resistance to FDA approved agents. Initial clinical data also confirm potent BTK degradation with once daily oral dosing. Currently, the drug is in the Phase I stage of its development for the treatment of Follicular Lymphoma.

The Follicular Lymphoma pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
* Follicular Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.

Explore the dynamic world of drug development with our latest Follicular Lymphoma Pipeline Insights report! Don't miss this opportunity to stay informed-download now! @ Follicular Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Follicular Lymphoma Companies

Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene and others.

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Follicular Lymphoma Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Learn more about the emerging Follicular Lymphoma Pipeline Therapies @ Follicular Lymphoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Follicular Lymphoma Pipeline Report

* Coverage- Global
* Follicular Lymphoma Companies- Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene and others.
* Follicular Lymphoma Pipeline Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera Registered , Epcoritamab, Rituximab, Lenalidomide, and others.
* Follicular Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Follicular Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Follicular Lymphoma Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!" @ Follicular Lymphoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/follicular-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Follicular Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Follicular Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* MIL62: MAB WORKS
* Mid Stage Products (Phase II)
* Abexinostat: Xynomic Pharmaceuticals
* Early Stage Products (Phase I)
* ABBV-319: AbbVie
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Follicular Lymphoma Key Companies
* Follicular Lymphoma Key Products
* Follicular Lymphoma- Unmet Needs
* Follicular Lymphoma- Market Drivers and Barriers
* Follicular Lymphoma- Future Perspectives and Conclusion
* Follicular Lymphoma Analyst Views
* Follicular Lymphoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=follicular-lymphoma-pipeline-outlook-report-2025-key-45-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/follicular-lymphoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.